Eric Jonasch1, Frede Donskov1, Othon Iliopoulos1, W Kimryn Rathmell1, Vivek K Narayan1, Benjamin L Maughan1, Stephane Oudard1, Tobias Else1, Jodi K Maranchie1, Sarah J Welsh1, Sanjay Thamake1, Eric K Park1, Rodolfo F Perini1, W Marston Linehan1, Ramaprasad Srinivasan1. 1. From the University of Texas M.D. Anderson Cancer Center, Houston (E.J.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston (O.I.); Vanderbilt University Medical Center, Nashville (W.K.R.); University of Pennsylvania, Philadelphia (V.K.N.); the University of Utah, Salt Lake City (B.L.M.); Hôpital Européen Georges-Pompidou, University of Paris, Paris (S.O.); the University of Michigan, Ann Arbor (T.E.); the University of Pittsburgh, Pittsburgh (J.K.M.); Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom (S.J.W.); Merck, Kenilworth, NJ (S.T., E.K.P., R.F.P.); and the Center for Cancer Research, National Cancer Institute, Bethesda, MD (W.M.L., R.S.).
Abstract
BACKGROUND: Patients with von Hippel-Lindau (VHL) disease have a high incidence of renal cell carcinoma owing to VHL gene inactivation and constitutive activation of the transcription factor hypoxia-inducible factor 2α (HIF-2α). METHODS: In this phase 2, open-label, single-group trial, we investigated the efficacy and safety of the HIF-2α inhibitor belzutifan (MK-6482, previously called PT2977), administered orally at a dose of 120 mg daily, in patients with renal cell carcinoma associated with VHL disease. The primary end point was objective response (complete or partial response) as measured according to the Response Evaluation Criteria in Solid Tumors, version 1.1, by an independent central radiology review committee. We also assessed responses to belzutifan in patients with non-renal cell carcinoma neoplasms and the safety of belzutifan. RESULTS: After a median follow-up of 21.8 months (range, 20.2 to 30.1), the percentage of patients with renal cell carcinoma who had an objective response was 49% (95% confidence interval, 36 to 62). Responses were also observed in patients with pancreatic lesions (47 of 61 patients [77%]) and central nervous system hemangioblastomas (15 of 50 patients [30%]). Among the 16 eyes that could be evaluated in 12 patients with retinal hemangioblastomas at baseline, all (100%) were graded as showing improvement. The most common adverse events were anemia (in 90% of the patients) and fatigue (in 66%). Seven patients discontinued treatment: four patients voluntarily discontinued, one discontinued owing to a treatment-related adverse event (grade 1 dizziness), one discontinued because of disease progression as assessed by the investigator, and one patient died (of acute toxic effects of fentanyl). CONCLUSIONS: Belzutifan was associated with predominantly grade 1 and 2 adverse events and showed activity in patients with renal cell carcinomas and non-renal cell carcinoma neoplasms associated with VHL disease. (Funded by Merck Sharp and Dohme and others; MK-6482-004 ClinicalTrials.gov number, NCT03401788.).
BACKGROUND: Patients with von Hippel-Lindau (VHL) disease have a high incidence of renal cell carcinoma owing to VHL gene inactivation and constitutive activation of the transcription factor hypoxia-inducible factor 2α (HIF-2α). METHODS: In this phase 2, open-label, single-group trial, we investigated the efficacy and safety of the HIF-2α inhibitor belzutifan (MK-6482, previously called PT2977), administered orally at a dose of 120 mg daily, in patients with renal cell carcinoma associated with VHL disease. The primary end point was objective response (complete or partial response) as measured according to the Response Evaluation Criteria in Solid Tumors, version 1.1, by an independent central radiology review committee. We also assessed responses to belzutifan in patients with non-renal cell carcinoma neoplasms and the safety of belzutifan. RESULTS: After a median follow-up of 21.8 months (range, 20.2 to 30.1), the percentage of patients with renal cell carcinoma who had an objective response was 49% (95% confidence interval, 36 to 62). Responses were also observed in patients with pancreatic lesions (47 of 61 patients [77%]) and central nervous system hemangioblastomas (15 of 50 patients [30%]). Among the 16 eyes that could be evaluated in 12 patients with retinal hemangioblastomas at baseline, all (100%) were graded as showing improvement. The most common adverse events were anemia (in 90% of the patients) and fatigue (in 66%). Seven patients discontinued treatment: four patients voluntarily discontinued, one discontinued owing to a treatment-related adverse event (grade 1 dizziness), one discontinued because of disease progression as assessed by the investigator, and one patient died (of acute toxic effects of fentanyl). CONCLUSIONS: Belzutifan was associated with predominantly grade 1 and 2 adverse events and showed activity in patients with renal cell carcinomas and non-renal cell carcinoma neoplasms associated with VHL disease. (Funded by Merck Sharp and Dohme and others; MK-6482-004 ClinicalTrials.gov number, NCT03401788.).
Authors: Eric Jonasch; Ian E McCutcheon; Dan S Gombos; Kamran Ahrar; Nancy D Perrier; Diane Liu; Christine C Robichaux; Mercedes F Villarreal; Justin A Weldon; Ashley H Woodson; Patrick G Pilie; Gregory N Fuller; Steven G Waguespack; Surena F Matin Journal: Lancet Oncol Date: 2018-09-17 Impact factor: 41.316
Authors: Kevin D Courtney; Yuanqing Ma; Alberto Diaz de Leon; Alana Christie; Zhiqun Xie; Layton Woolford; Nirmish Singla; Allison Joyce; Haley Hill; Ananth J Madhuranthakam; Qing Yuan; Yin Xi; Yue Zhang; Jenny Chang; Oluwatomilade Fatunde; Yull Arriaga; Arthur E Frankel; Sanjeeva Kalva; Song Zhang; Tiffani McKenzie; Oscar Reig Torras; Robert A Figlin; Brian I Rini; Renée M McKay; Payal Kapur; Tao Wang; Ivan Pedrosa; James Brugarolas Journal: Clin Cancer Res Date: 2019-11-14 Impact factor: 12.531
Authors: Marzia Scortegagna; Kan Ding; Quiyang Zhang; Yavuz Oktay; Michael J Bennett; Michael Bennett; John M Shelton; James A Richardson; Orson Moe; Joseph A Garcia Journal: Blood Date: 2004-12-30 Impact factor: 22.113
Authors: Toni K Choueiri; Todd M Bauer; Kyriakos P Papadopoulos; Elizabeth R Plimack; Jaime R Merchan; David F McDermott; M Dror Michaelson; Leonard J Appleman; Sanjay Thamake; Rodolfo F Perini; Naseem J Zojwalla; Eric Jonasch Journal: Nat Med Date: 2021-04-22 Impact factor: 87.241
Authors: Hyejin Cho; Xinlin Du; James P Rizzi; Ella Liberzon; Abhishek A Chakraborty; Wenhua Gao; Ingrid Carvo; Sabina Signoretti; Richard K Bruick; John A Josey; Eli M Wallace; William G Kaelin Journal: Nature Date: 2016-09-05 Impact factor: 49.962
Authors: Jacob J Adashek; Joshua J Breunig; Edwin Posadas; Neil A Bhowmick; Leigh Ellis; Stephen J Freedland; Hyung Kim; Robert Figlin; Jun Gong Journal: Drugs Date: 2022-02-17 Impact factor: 9.546
Authors: Ameish Govindarajan; Daniela V Castro; Zeynep B Zengin; Sabrina K Salgia; Jalen Patel; Sumanta K Pal Journal: Cancers (Basel) Date: 2022-04-19 Impact factor: 6.575
Authors: Carolina J Garcia Garcia; Yanqing Huang; Natividad R Fuentes; Madeleine C Turner; Maria E Monberg; Daniel Lin; Nicholas D Nguyen; Tara N Fujimoto; Jun Zhao; Jaewon J Lee; Vincent Bernard; Meifang Yu; Abagail M Delahoussaye; Iancarlos Jimenez Sacarello; Emily G Caggiano; Jae L Phan; Amit Deorukhkar; Jessica M Molkentine; Dieter Saur; Anirban Maitra; Cullen M Taniguchi Journal: Gastroenterology Date: 2022-02-22 Impact factor: 33.883